Cargando…
Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose.
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Association for the Study of the Liver. Published by Elsevier B.V.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252397/ http://dx.doi.org/10.1016/S0168-8278(22)02112-2 |
| _version_ | 1784740255710052352 |
|---|---|
| author | Sempere, Elena Diago Matilla, Ana Rodríguez, Carlos Perelló, Christie Minguez, Beatriz Varela, Maria Urquijo, Juan José Ampuero, Javier Prieto, Janire Pérez, Laura Márquez Crespo, Javier Bermúdez, María Piedra Cerezal, Ana Maria Diago, Moises Antoran, Belén Ruiz Calleja Panero, José Luis |
| author_facet | Sempere, Elena Diago Matilla, Ana Rodríguez, Carlos Perelló, Christie Minguez, Beatriz Varela, Maria Urquijo, Juan José Ampuero, Javier Prieto, Janire Pérez, Laura Márquez Crespo, Javier Bermúdez, María Piedra Cerezal, Ana Maria Diago, Moises Antoran, Belén Ruiz Calleja Panero, José Luis |
| author_sort | Sempere, Elena Diago |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9252397 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Association for the Study of the Liver. Published by Elsevier B.V. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92523972022-07-05 Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose. Sempere, Elena Diago Matilla, Ana Rodríguez, Carlos Perelló, Christie Minguez, Beatriz Varela, Maria Urquijo, Juan José Ampuero, Javier Prieto, Janire Pérez, Laura Márquez Crespo, Javier Bermúdez, María Piedra Cerezal, Ana Maria Diago, Moises Antoran, Belén Ruiz Calleja Panero, José Luis J Hepatol POSTER PRESENTATIONS: Saturday 25 June: Liver tumours: Clinical aspects except therapy European Association for the Study of the Liver. Published by Elsevier B.V. 2022-07 2022-07-04 /pmc/articles/PMC9252397/ http://dx.doi.org/10.1016/S0168-8278(22)02112-2 Text en Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | POSTER PRESENTATIONS: Saturday 25 June: Liver tumours: Clinical aspects except therapy Sempere, Elena Diago Matilla, Ana Rodríguez, Carlos Perelló, Christie Minguez, Beatriz Varela, Maria Urquijo, Juan José Ampuero, Javier Prieto, Janire Pérez, Laura Márquez Crespo, Javier Bermúdez, María Piedra Cerezal, Ana Maria Diago, Moises Antoran, Belén Ruiz Calleja Panero, José Luis Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose. |
| title | Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose. |
| title_full | Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose. |
| title_fullStr | Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose. |
| title_full_unstemmed | Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose. |
| title_short | Safety and effectiveness of vaccines agains SARS-COV-2 in patients with liver cancer. VacHep registry: response analysis 4 weeks after the second dose. |
| title_sort | safety and effectiveness of vaccines agains sars-cov-2 in patients with liver cancer. vachep registry: response analysis 4 weeks after the second dose. |
| topic | POSTER PRESENTATIONS: Saturday 25 June: Liver tumours: Clinical aspects except therapy |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252397/ http://dx.doi.org/10.1016/S0168-8278(22)02112-2 |
| work_keys_str_mv | AT sempereelenadiago safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT matillaana safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT rodriguezcarlos safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT perellochristie safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT minguezbeatriz safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT varelamaria safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT urquijojuanjose safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT ampuerojavier safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT prietojanire safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT perezlauramarquez safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT crespojavier safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT bermudezmaria safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT piedracerezalanamaria safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT diagomoises safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT antoranbelenruiz safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose AT callejapanerojoseluis safetyandeffectivenessofvaccinesagainssarscov2inpatientswithlivercancervachepregistryresponseanalysis4weeksaftertheseconddose |